{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T16:58:40Z","timestamp":1778691520491,"version":"3.51.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2008,4,30]],"date-time":"2008-04-30T00:00:00Z","timestamp":1209513600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1007\/s00403-008-0853-2","type":"journal-article","created":{"date-parts":[[2008,4,29]],"date-time":"2008-04-29T08:43:18Z","timestamp":1209458598000},"page":"505-516","source":"Crossref","is-referenced-by-count":10,"title":["Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase"],"prefix":"10.1007","volume":"300","author":[{"given":"Sofi","family":"Forsberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"\u00d6stman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ola","family":"Rollman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,4,30]]},"reference":[{"key":"853_CR1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.2002.20.1.110","volume":"20","author":"J Albanell","year":"2002","unstructured":"Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20:110\u2013124","journal-title":"J Clin Oncol"},{"key":"853_CR2","first-page":"4450","volume":"63","author":"EG Barbacci","year":"2003","unstructured":"Barbacci EG, Pustilnik LR, Rossi AM, Emerson E, Miller PE, Boscoe BP, Cox ED, Iwata KK, Jani JP, Provoncha K, Kath JC, Liu Z, Moyer JD (2003) The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells. Cancer Res 63:4450\u20134459","journal-title":"Cancer Res"},{"issue":"Suppl 4","key":"853_CR3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1634\/theoncologist.7-suppl_4-2","volume":"7","author":"J Baselga","year":"2002","unstructured":"Baselga J (2002) Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7(Suppl 4):2\u20138","journal-title":"Oncologist"},{"key":"853_CR4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1600-0625.1995.tb00227.x","volume":"4","author":"H Ben-Bassat","year":"1995","unstructured":"Ben-Bassat H, Vardi DV, Gazit A, Klaus SN, Chaouat M, Hartzstark Z, Levitzki A (1995) Tyrphostins suppress the growth of psoriatic keratinocytes. Exp Dermatol 4:82\u201388","journal-title":"Exp Dermatol"},{"key":"853_CR5","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2174\/1381612003400182","volume":"6","author":"H Ben-Bassat","year":"2000","unstructured":"Ben-Bassat H, Klein BY (2000) Inhibitors of tyrosine kinases in the treatment of psoriasis. Curr Pharm Des 6:933\u2013942","journal-title":"Curr Pharm Des"},{"key":"853_CR6","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1365-2133.1985.tb02332.x","volume":"112","author":"BA Bernard","year":"1985","unstructured":"Bernard BA, Robinson SM, Vandaele S, Mansbridge JN, Darmon M (1985) Abnormal maturation pathway of keratinocytes in psoriatic skin. Br J Dermatol 112:647\u2013653","journal-title":"Br J Dermatol"},{"key":"853_CR7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1006\/excr.1994.1093","volume":"211","author":"R Bertrand","year":"1994","unstructured":"Bertrand R, Solary E, O\u2019Connor P, Kohn KW, Pommier Y (1994) Induction of a common pathway of apoptosis by staurosporine. Exp Cell Res 211:314\u2013321","journal-title":"Exp Cell Res"},{"key":"853_CR8","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1046\/j.1365-2133.1999.03205.x","volume":"141","author":"M Bhushan","year":"1999","unstructured":"Bhushan M, McLaughlin B, Weiss JB, Griffiths CE (1999) Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 141:1054\u20131060","journal-title":"Br J Dermatol"},{"key":"853_CR9","first-page":"3224","volume":"52","author":"PW Cook","year":"1992","unstructured":"Cook PW, Pittelkow MR, Keeble WW, Graves-Deal R, Coffey RJ Jr, Shipley GD (1992) Amphiregulin messenger RNA is elevated in psoriatic epidermis and gastrointestinal carcinomas. Cancer Res 52:3224\u20133227","journal-title":"Cancer Res"},{"key":"853_CR10","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1084\/jem.180.3.1141","volume":"180","author":"M Detmar","year":"1994","unstructured":"Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, Berse B, Dvorak HF (1994) Overexpression of vascular permeability factor\/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 180:1141\u20131146","journal-title":"J Exp Med"},{"key":"853_CR11","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1126\/science.2916128","volume":"243","author":"JT Elder","year":"1989","unstructured":"Elder JT, Fisher GJ, Lindquist PB, Bennett GL, Pittelkow MR, Coffey RJ Jr, Ellingsworth L, Derynck R, Voorhees JJ (1989) Overexpression of transforming growth factor alpha in psoriatic epidermis. Science 243:811\u2013814","journal-title":"Science"},{"key":"853_CR12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2340\/00015555-0089","volume":"86","author":"S Forsberg","year":"2006","unstructured":"Forsberg S, Saarialho-Kere U, Rollman O (2006) Comparison of growth-inhibitory agents by fluorescence imaging of human skin re-epithelialization in vitro. Acta Derm Venereol 86:292\u2013299","journal-title":"Acta Derm Venereol"},{"key":"853_CR13","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1084\/jem.167.2.670","volume":"167","author":"AB Gottlieb","year":"1988","unstructured":"Gottlieb AB, Chang CK, Posnett DN, Fanelli B, Tam JP (1988) Detection of transforming growth factor alpha in normal, malignant, and hyperproliferative human keratinocytes. J Exp Med 167:670\u2013675","journal-title":"J Exp Med"},{"key":"853_CR14","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/(SICI)1097-0029(19981201)43:5<444::AID-JEMT10>3.0.CO;2-C","volume":"43","author":"LG Hudson","year":"1998","unstructured":"Hudson LG, McCawley LJ (1998) Contributions of the epidermal growth factor receptor to keratinocyte motility. Microsc Res Tech 43:444\u2013455","journal-title":"Microsc Res Tech"},{"key":"853_CR15","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1073\/pnas.90.14.6786","volume":"90","author":"CK Jiang","year":"1993","unstructured":"Jiang CK, Magnaldo T, Ohtsuki M, Freedberg IM, Bernerd F, Blumenberg M (1993) Epidermal growth factor and transforming growth factor alpha specifically induce the activation- and hyperproliferation-associated keratins 6 and 16. Proc Natl Acad Sci USA 90:6786\u20136790","journal-title":"Proc Natl Acad Sci USA"},{"key":"853_CR16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1023\/A:1003287101868","volume":"30","author":"I Johnson","year":"1998","unstructured":"Johnson I (1998) Fluorescent probes for living cells. Histochem J 30:123\u2013140","journal-title":"Histochem J"},{"key":"853_CR17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1523-1747.1999.00543.x","volume":"112","author":"M Jost","year":"1999","unstructured":"Jost M, Class R, Kari C, Jensen PJ, Rodeck U (1999) A central role of Bcl-X(L) in the regulation of keratinocyte survival by autocrine EGFR ligands. J Invest Dermatol 112:443\u2013449","journal-title":"J Invest Dermatol"},{"key":"853_CR18","doi-asserted-by":"crossref","first-page":"10S","DOI":"10.1111\/1523-1747.ep12505661","volume":"95","author":"LE King Jr","year":"1990","unstructured":"King LE Jr, Gates RE, Stoscheck CM, Nanney LB (1990) Epidermal growth factor\/transforming growth factor alpha receptors and psoriasis. J Invest Dermatol 95:10S\u201312S","journal-title":"J Invest Dermatol"},{"key":"853_CR19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0959-8049(00)00364-6","volume":"37","author":"G Krahn","year":"2001","unstructured":"Krahn G, Leiter U, Kaskel P, Udart M, Utikal J, Bezold G, Peter RU (2001) Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. Eur J Cancer 37:251\u2013259","journal-title":"Eur J Cancer"},{"key":"853_CR20","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1006\/bbrc.2001.4943","volume":"284","author":"E Lee","year":"2001","unstructured":"Lee E, Jeon SH, Yi JY, Jin YJ, Son YS (2001) Calcipotriol inhibits autocrine phosphorylation of EGF receptor in a calcium-dependent manner, a possible mechanism for its inhibition of cell proliferation and stimulation of cell differentiation. Biochem Biophys Res Commun 284:419\u2013425","journal-title":"Biochem Biophys Res Commun"},{"key":"853_CR21","first-page":"23","volume":"84","author":"MW Lee","year":"2004","unstructured":"Lee MW, Seo CW, Kim SW, Yang HJ, Lee HW, Choi JH, Moon KC, Koh JK (2004) Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol 84:23\u201326","journal-title":"Acta Derm Venereol"},{"key":"853_CR22","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2133.1995.tb02696.x","volume":"133","author":"IM Leigh","year":"1995","unstructured":"Leigh IM, Navsaria H, Purkis PE, McKay IA, Bowden PE, Riddle PN (1995) Keratins (K16 and K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro. Br J Dermatol 133:501\u2013511","journal-title":"Br J Dermatol"},{"key":"853_CR23","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1126\/science.7892601","volume":"267","author":"A Levitzki","year":"1995","unstructured":"Levitzki A, Gazit A (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267:1782\u20131788","journal-title":"Science"},{"key":"853_CR24","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1067-1927.2004.012510.x","volume":"12","author":"H Lu","year":"2004","unstructured":"Lu H, Rollman O (2004) Fluorescence imaging of reepithelialization from skin explant cultures on acellular dermis. Wound Repair Regen 12:575\u2013586","journal-title":"Wound Repair Regen"},{"key":"853_CR25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0002-9440(10)63654-1","volume":"163","author":"F Mascia","year":"2003","unstructured":"Mascia F, Mariani V, Girolomoni G, Pastore S (2003) Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 163:303\u2013312","journal-title":"Am J Pathol"},{"key":"853_CR26","first-page":"1205","volume":"25","author":"E Maubec","year":"2005","unstructured":"Maubec E, Duvillard P, Velasco V, Crickx B, Avril MF (2005) Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin. Anticancer Res 25:1205\u20131210","journal-title":"Anticancer Res"},{"key":"853_CR27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1046\/j.1432-0436.1994.5810077.x","volume":"58","author":"V Mils","year":"1994","unstructured":"Mils V, Basset-Seguin N, Moles JP, Tesniere A, Leigh I, Guilhou JJ (1994) Comparative analysis of normal and psoriatic skin both in vivo and in vitro. Differentiation 58:77\u201386","journal-title":"Differentiation"},{"key":"853_CR28","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1046\/j.1365-2133.2002.497217.x","volume":"147","author":"S Miyagawa","year":"2002","unstructured":"Miyagawa S, Fujimoto H, Ko S, Hirota S, Kitamura Y (2002) Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour. Br J Dermatol 147:406\u2013407","journal-title":"Br J Dermatol"},{"key":"853_CR29","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/1523-1747.ep12259731","volume":"82","author":"LB Nanney","year":"1984","unstructured":"Nanney LB, McKanna JA, Stoscheck CM, Carpenter G, King LE (1984) Visualization of epidermal growth factor receptors in human epidermis. J Invest Dermatol 82:165\u2013169","journal-title":"J Invest Dermatol"},{"key":"853_CR30","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/1523-1747.ep12285389","volume":"86","author":"LB Nanney","year":"1986","unstructured":"Nanney LB, Stoscheck CM, Magid M, King LE Jr (1986) Altered [125I]epidermal growth factor binding and receptor distribution in psoriasis. J Invest Dermatol 86:260\u2013265","journal-title":"J Invest Dermatol"},{"key":"853_CR31","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/1523-1747.ep12340759","volume":"109","author":"D Peus","year":"1997","unstructured":"Peus D, Hamacher L, Pittelkow MR (1997) EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation. J Invest Dermatol 109:751\u2013756","journal-title":"J Invest Dermatol"},{"key":"853_CR32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00000372-199604000-00010","volume":"18","author":"M Piepkorn","year":"1996","unstructured":"Piepkorn M (1996) Overexpression of amphiregulin, a major autocrine growth factor for cultured human keratinocytes, in hyperproliferative skin diseases. Am J Dermatopathol 18:165\u2013171","journal-title":"Am J Dermatopathol"},{"key":"853_CR33","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1046\/j.1523-1747.1998.00390.x","volume":"111","author":"M Piepkorn","year":"1998","unstructured":"Piepkorn M, Pittelkow MR, Cook PW (1998) Autocrine regulation of keratinocytes: the emerging role of heparin-binding, epidermal growth factor-related growth factors. J Invest Dermatol 111:715\u2013721","journal-title":"J Invest Dermatol"},{"key":"853_CR34","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00403-003-0391-x","volume":"295","author":"M Piepkorn","year":"2003","unstructured":"Piepkorn M, Predd H, Underwood R, Cook P (2003) Proliferation\u2013differentiation relationships in the expression of heparin-binding epidermal growth factor-related factors and erbB receptors by normal and psoriatic human keratinocytes. Arch Dermatol Res 295:93\u2013101","journal-title":"Arch Dermatol Res"},{"key":"853_CR35","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4419-0318-1","volume-title":"Mixed-effects models in S and S-PLUS","author":"JC Pinheiro","year":"2000","unstructured":"Pinheiro JC, Bates DM (2000) Mixed-effects models in S and S-PLUS. Springer, New York"},{"key":"853_CR36","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1073\/pnas.90.5.1746","volume":"90","author":"GD Plowman","year":"1993","unstructured":"Plowman GD, Culouscou JM, Whitney GS, Green JM, Carlton GW, Foy L, Neubauer MG, Shoyab M (1993) Ligand-specific activation of HER4\/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90:1746\u20131750","journal-title":"Proc Natl Acad Sci USA"},{"key":"853_CR37","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1046\/j.1365-2133.1999.03152.x","volume":"141","author":"TJ Powell","year":"1999","unstructured":"Powell TJ, Ben-Bassat H, Klein BY, Chen H, Shenoy N, McCollough J, Narog B, Gazit A, Harzstark Z, Chaouat M, Levitzki R, Tang C, McMahon J, Shawver L, Levitzki A (1999) Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors. Br J Dermatol 141:802\u2013810","journal-title":"Br J Dermatol"},{"key":"853_CR38","first-page":"953","volume":"5","author":"MF Press","year":"1990","unstructured":"Press MF, Cordon-Cardo C, Slamon DJ (1990) Expression of the HER-2\/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5:953\u2013962","journal-title":"Oncogene"},{"key":"853_CR39","first-page":"1273","volume":"7","author":"SA Prigent","year":"1992","unstructured":"Prigent SA, Lemoine NR, Hughes CM, Plowman GD, Selden C, Gullick WJ (1992) Expression of the c-erbB-3 protein in normal human adult and fetal tissues. Oncogene 7:1273\u20131278","journal-title":"Oncogene"},{"key":"853_CR40","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000210854","volume":"3","author":"M Regnier","year":"1990","unstructured":"Regnier M, Asselineau D, Lenoir MC (1990) Human epidermis reconstructed on dermal substrates in vitro: an alternative to animals in skin pharmacology. Skin Pharmacol 3:70\u201385","journal-title":"Skin Pharmacol"},{"key":"853_CR41","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1600-0625.1997.tb00165.x","volume":"6","author":"K Rikimaru","year":"1997","unstructured":"Rikimaru K, Moles JP, Watt FM (1997) Correlation between hyperproliferation and suprabasal integrin expression in human epidermis reconstituted in culture. Exp Dermatol 6:214\u2013221","journal-title":"Exp Dermatol"},{"key":"853_CR42","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","volume":"16","author":"S Segaert","year":"2005","unstructured":"Segaert S, Van Cutsem E (2005) Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16:1425\u20131433","journal-title":"Ann Oncol"},{"key":"853_CR43","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0093-7754(01)90285-4","volume":"28","author":"WJ Slichenmyer","year":"2001","unstructured":"Slichenmyer WJ, Elliott WL, Fry DW (2001) CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin Oncol 28:80\u201385","journal-title":"Semin Oncol"},{"key":"853_CR44","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/(SICI)1096-9896(199807)185:3<236::AID-PATH118>3.0.CO;2-7","volume":"185","author":"R Srinivasan","year":"1998","unstructured":"Srinivasan R, Poulsom R, Hurst HC, Gullick WJ (1998) Expression of the c-erbB-4\/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J Pathol 185:236\u2013245","journal-title":"J Pathol"},{"key":"853_CR45","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/sj.neo.7900170","volume":"3","author":"SW Stoll","year":"2001","unstructured":"Stoll SW, Kansra S, Peshick S, Fry DW, Leopold WR, Wiesen JF, Sibilia M, Zhang T, Werb Z, Derynck R, Wagner EF, Elder JT (2001) Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes. Neoplasia 3:339\u2013350","journal-title":"Neoplasia"},{"key":"853_CR46","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/med.1022","volume":"21","author":"P Traxler","year":"2001","unstructured":"Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, O\u2019Reilly T, Wood J, Zimmermann J (2001) Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 21:499\u2013512","journal-title":"Med Res Rev"},{"key":"853_CR47","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1517\/14728222.7.2.215","volume":"7","author":"P Traxler","year":"2003","unstructured":"Traxler P (2003) Tyrosine kinases as targets in cancer therapy\u2014successes and failures. Expert Opin Ther Targets 7:215\u2013234","journal-title":"Expert Opin Ther Targets"},{"key":"853_CR48","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1158\/0008-5472.CAN-03-3681","volume":"64","author":"P Traxler","year":"2004","unstructured":"Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G (2004) AEE788: a dual family epidermal growth factor receptor\/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 64:4931\u20134941","journal-title":"Cancer Res"},{"key":"853_CR49","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000084909","volume":"18","author":"J Varani","year":"2005","unstructured":"Varani J, Lateef H, Fay K, Elder JT (2005) Antagonism of epidermal growth factor receptor tyrosine kinase ameliorates the psoriatic phenotype in organ-cultured skin. Skin Pharmacol Physiol 18:123\u2013131","journal-title":"Skin Pharmacol Physiol"},{"key":"853_CR50","first-page":"5749","volume":"62","author":"AE Wakeling","year":"2002","unstructured":"Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH (2002) ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62:5749\u20135754","journal-title":"Cancer Res"},{"key":"853_CR51","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1346-8138.1991.tb03057.x","volume":"18","author":"S Watanabe","year":"1991","unstructured":"Watanabe S, Wagatsuma K, Ichikawa E, Takahashi H (1991) Abnormal distribution of epidermal protein antigens in psoriatic epidermis. J Dermatol 18:143\u2013151","journal-title":"J Dermatol"},{"key":"853_CR52","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2133.2006.07299.x","volume":"155","author":"E Wierzbicka","year":"2006","unstructured":"Wierzbicka E, Tourani JM, Guillet G (2006) Improvement of psoriasis and cutaneous side-effects during tyrosine kinase inhibitor therapy for renal metastatic adenocarcinoma. A role for epidermal growth factor receptor (EGFR) inhibitors in psoriasis? Br J Dermatol 155:213\u2013214","journal-title":"Br J Dermatol"},{"key":"853_CR53","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0002-9440(10)61213-8","volume":"167","author":"TA Wilgus","year":"2005","unstructured":"Wilgus TA, Matthies AM, Radek KA, Dovi JV, Burns AL, Shankar R, DiPietro LA (2005) Novel function for vascular endothelial growth factor receptor-1 on epidermal keratinocytes. Am J Pathol 167:1257\u20131266","journal-title":"Am J Pathol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-008-0853-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00403-008-0853-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-008-0853-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T17:37:39Z","timestamp":1559065059000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00403-008-0853-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,30]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["853"],"URL":"https:\/\/doi.org\/10.1007\/s00403-008-0853-2","relation":{},"ISSN":["0340-3696","1432-069X"],"issn-type":[{"value":"0340-3696","type":"print"},{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,30]]}}}